NASDAQ · IMNN
Imunon, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IMNN: Nov 12, 2026
Imunon, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.61. The reported EPS for the same quarter last year was $-1.16.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.61 | $-0.56 | $-0.71 | 3 |
| Dec 2026 | $-0.47 | $-0.24 | $-0.71 | 3 |
| Mar 2027 | $-0.78 | $-0.78 | $-0.78 | 1 |
| Jun 2027 | $-0.76 | $-0.76 | $-0.76 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool- Fintel · Oct 21, 4:35 PM EDTImunon, Inc. Agrees to Sell ThermoDox Assets to VoxelDox Therapeutics, Inc. for Up to $16.5 million in MilestonesOn October 20, 2026, Imunon, Inc. entered into an Asset Purchase Agreement with VoxelDox Therapeutics, Inc., pursuant to which the Company agreed to sell to VoxelDox the Company’s assets relating to ThermoDox, a heat-activated liposomal formulation of doxorubicin, including
- RTTNews · Oct 21, 4:11 PM EDTBiotech Stocks Move Higher: IMNN Surges Over 18%, HSCS Gains Over 13%, SXTC Rises 7%(RTTNews) – Shares of several small-cap companies moved higher on Wednesday following corporate developments involving a proposed digital asset mining merger, a strategic drug asset sale and changes to securities offering terms. Imunon announced an agreement to sell its ThermoDox
- RTTNews · Oct 21, 8:42 AM EDTIMUNON To Sell ThermoDox Rights To VoxelDox For Glioblastoma Multiforme(RTTNews) – IMUNON, Inc. (IMNN) said Wednesday it agreed to sell its rights to ThermoDox to VoxelDox Therapeutics in exchange for an equity stake, potential milestone payments and royalties.
- RTTNews · Sep 26, 12:47 PM EDTIMUNON Reports Positive IDMC Opinion For IMNN-001 In Ovarian Cancer(RTTNews) – IMUNON Inc. (IMNN), a clinical-stage biotechnology company, last week announced a positive recommendation from an Independent Data Monitoring Committee (IDMC) regarding Phase 2 minimal residue disease (MRD) trial for IMNN-001 in ovarian cancer. IMNN-001 is an IL-12
- RTTNews · Sep 25, 10:53 AM EDTWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) – Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across oncology, metabolic diseases, immunology and rare diseases.
- RTTNews · Sep 24, 9:59 AM EDTIMUNON Highlights 14.7-Month Survival Benefit For IMNN-001; OVATION 3 Enrollment Ahead Of Plan(RTTNews) – IMUNON, Inc. (IMNN) highlighted final Phase 2 overall survival results for IMNN-001 in newly diagnosed advanced ovarian cancer, showing a 14.7-month median overall survival benefit versus standard-of-care chemotherapy alone, while enrollment in the ongoing pivotal Pha
- RTTNews · Sep 10, 10:33 AM EDTIMUNON Enters CRADA With NCI To Advance IMNN-001 Clinical Development(RTTNews) – IMUNON Inc. (IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to advance the clinical and non-clinical
- The Motley Fool · Aug 11, 10:12 PM EDTImunon (IMNN) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 11, 2:51 PM EDTIMUNON Advances OVATION 3 Trial Of IMNN-001; Enrollment Expected To Complete In 1H29(RTTNews) – IMUNON, Inc. (IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, reported its second-quarter 2026 financial results and provided a business update, with investors focusing on continued progress in the pivotal Phase 3 OVATION 3 trial
- RTTNews · Jul 21, 11:40 AM EDTIMUNON Phase 2 Data Show IMNN-001 Improves MRD Outcomes In Ovarian Cancer(RTTNews) – IMUNON, Inc. (IMNN), a clinical-stage biotechnology company, announced Tuesday positive preliminary data from the ongoing Phase 2 minimal residual disease (MRD) trial evaluating IMNN-001 in combination with standard-of-care chemotherapy and bevacizumab in women with n
- RTTNews · Jun 26, 10:33 AM EDTWeekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired(RTTNews) – This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology.
- RTTNews · Jun 23, 10:37 AM EDTIMUNON's Phase 3 OVATION 3 Trial Clears Key Safety Review, Continues Without Modification(RTTNews) – IMUNON, Inc. (IMNN) announced that an independent Data Monitoring Committee has recommended the continuation of the pivotal Phase 3 OVATION 3 trial without any changes, following a scheduled interim safety and efficacy review.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Imunon, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.